ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Dexamethasone

Also written as “dexamethasone”, “OTO-104” and “Dexycu”.

Its studies are mostly in Multiple Myeloma · Cataract · Macular Edema · Meniere Disease · Conjunctivitis, Allergic, led by 30 companies.

Drug pageDexamethasone: every studyMany companies study it; this page follows only the 92 they lead. All 1,797 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Mar 6, 200392 company-led studies, 7 open or runningNext primary completion: Apr 1, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibbits history only200 open or runningphase 3since Mar 6, 2003Mar 6, 2003none ahead
Ocular Therapeutixits history only100 open or runningphase 3since Jan 9, 2014Jan 9, 2014none ahead
Takedaits history only100 open or runningphase 4since May 30, 2017Jul 25, 2007none ahead
Oculisits history only50 open or runningphase 3since Sep 2, 2021Oct 16, 2019none ahead
Sun Pharmaceutical Industriesits history only50 open or runningphase 3since Dec 19, 2007Dec 19, 2007none ahead
Oncotherapeuticsits history only40 open or runningphase 2since Aug 26, 2008Aug 26, 2008none ahead
EyePoint Pharmaceuticalsits history only30 open or runningphase 4since Dec 13, 2021Dec 13, 2021none ahead
Hamad Medicalits history only32 open or runningphase 3since Nov 30, 2020Jan 12, 2010none ahead
Sanofiits history only33 open or runningphase 2since Oct 20, 2020Oct 20, 2020Apr 1, 2027phase 2 · NCT06356571
Alconits history only20 open or runningphase 4since Feb 29, 2008Feb 29, 2008none ahead
Travanti Pharma10 open or runningphase 1since May 6, 2009May 6, 2009none ahead

Also a collaborator on its studies: Karyopharm Therapeutics, AbbVie, Onyx Therapeutics, Abbott, Tigermed Consulting, Accelovance, ORA, Johnson & Johnson, Hoffmann-La Roche, Amgen, Novum Pharmaceutical Research Services, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA and Prologue Research International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Travanti Pharma only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. May 6, 2009First study: phase 1 study in Tennis ElbowFirst studyNCT00895076 · 12 enrolled · United States
  2. Aug 6, 2023Named dexamethasoneINNProposed as its International Nonproprietary Name in WHO's List 129 · before, OTO-104

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
TriamcinoloneruleResearch Insightphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Travanti Pharma leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT00895076Tennis Elbow · United States1UNKNOWNMay 200912

How it is read

Names in the registry

  • “Dexamethasone”, 94 entries
  • “dexamethasone”, 20 entries
  • “OTO-104”, 9 entries
  • “Dexycu”, 4 entries
  • “Dexamethasone Oral”, 3 entries

Codes read as this program: OCS01.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.